NASDAQ:RYTM

Rhythm Pharmaceuticals Stock Forecast, Price & News

$28.98

-3.02 (-9.44 %)

(As of 12/3/2020 12:00 AM ET)

Add

Compare

Today's Range

$28.67

Now: $28.98▼

$32.29

50-Day Range

$21.17

MA: $23.71▼

$32.61

52-Week Range

$12.99

Now: $28.98▼

$34.27

Volume757,428 shs

Average Volume264,261 shs

Market Capitalization$1.28 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.3

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and AlstrÃ¶m syndrome; and is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Rhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $34.57, Rhythm Pharmaceuticals has a forecasted upside of 19.3% from its current price of $28.98.
Amount of Analyst Coverage
Rhythm Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Rhythm Pharmaceuticals has received 234 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Rhythm Pharmaceuticals has received 227 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Rhythm Pharmaceuticals has received 50.76% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Rhythm Pharmaceuticals and other stocks. Vote “Outperform” if you believe RYTM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RYTM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Rhythm Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rhythm Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rhythm Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.49% of the stock of Rhythm Pharmaceuticals is held by insiders.
Percentage Held by Institutions
92.97% of the stock of Rhythm Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($3.31) to ($1.98) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rhythm Pharmaceuticals is -8.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rhythm Pharmaceuticals is -8.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rhythm Pharmaceuticals has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.42 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:RYTM

Previous Symbol

CUSIPN/A

CIK1649904

Webwww.rhythmtx.com

Phone857-264-4280

Employees70

Debt

Debt-to-Equity RatioN/A

Current Ratio15.96

Quick Ratio15.96

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.40 per share

Price / Book4.53

Profitability

EPS (Most Recent Fiscal Year)($3.86)

Net Income$-140,730,000.00

Net MarginsN/A

Return on Equity-59.07%

Return on Assets-53.52%

Miscellaneous

Outstanding Shares44,205,000

Market Cap$1.28 billion

Next Earnings Date3/1/2021 (Estimated)

OptionableOptionable

$28.98

-3.02 (-9.44 %)

(As of 12/3/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

How has Rhythm Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RYTM shares have increased by 93.2% and is now trading at $28.98.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Rhythm Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Rhythm Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Rhythm Pharmaceuticals?

Wall Street analysts have given Rhythm Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rhythm Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Rhythm Pharmaceuticals' next earnings date?

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Rhythm Pharmaceuticals.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings data on Monday, November, 2nd. The company reported ($0.77) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.80) by $0.03.
View Rhythm Pharmaceuticals' earnings history.

What price target have analysts set for RYTM?

7 brokerages have issued 1 year price targets for Rhythm Pharmaceuticals' stock. Their forecasts range from $18.00 to $43.00. On average, they anticipate Rhythm Pharmaceuticals' share price to reach $34.57 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals.

Who are some of Rhythm Pharmaceuticals' key competitors?

Some companies that are related to Rhythm Pharmaceuticals include Turning Point Therapeutics (TPTX), Reata Pharmaceuticals (RETA), Schrödinger (SDGR), PTC Therapeutics (PTCT), Emergent BioSolutions (EBS), GW Pharmaceuticals (GWPH), Legend Biotech (LEGN), Insmed (INSM), Hutchison China MediTech (HCM), ChemoCentryx (CCXI), Hypera (HYPMY), Arena Pharmaceuticals (ARNA), FibroGen (FGEN), MorphoSys (MOR) and TG Therapeutics (TGTX).
View all competitors.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the following people:

Dr. David P. Meeker, Chairman, Pres & CEO (Age 66, Pay $85.5k)
Mr. Hunter C. Smith, CFO, Treasurer & Sec. (Age 51, Pay $636.79k)
Mr. Joseph Shulman, Sr. VP of Technical Operations
Mr. David Connolly, Head of Investor Relations & Corp. Communications
Mr. Simon D. Kelner, Chief HR Officer (Age 46)
Dr. Murray W. Stewart M.D., Chief Medical Officer (Age 59)
Dr. Alastair Garfield, VP of Translational R&D
Mr. Yann Mazabraud, Exec. VP & Head of International (Age 47)
Mr. John J. Hulburt CPA, Controller (Age 53)

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.97%), Federated Hermes Inc. (5.13%), State Street Corp (2.00%), Samsara BioCapital LLC (0.53%), Charles Schwab Investment Management Inc. (0.47%) and JPMorgan Chase & Co. (0.21%). Company insiders that own Rhythm Pharmaceuticals stock include Der Ploeg Leonardus HT Van, Keith Michael Gottesdiener, Nithya Desikan, Ra Capital Management, LP and Todd Foley.
View institutional ownership trends for Rhythm Pharmaceuticals.

Which institutional investors are selling Rhythm Pharmaceuticals stock?

RYTM stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, BlackRock Inc., Samsara BioCapital LLC, Morgan Stanley, JPMorgan Chase & Co., Wells Fargo & Company MN, Charles Schwab Investment Management Inc., and Virtus ETF Advisers LLC. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Nithya Desikan, Ra Capital Management, LP, and Todd Foley.
View insider buying and selling activity for Rhythm Pharmaceuticals.

Which institutional investors are buying Rhythm Pharmaceuticals stock?

RYTM stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Voloridge Investment Management LLC, Aperio Group LLC, WINTON GROUP Ltd, UBS Asset Management Americas Inc., DekaBank Deutsche Girozentrale, Squarepoint Ops LLC, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Rhythm Pharmaceuticals.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $28.98.

How big of a company is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals has a market capitalization of $1.28 billion. The company earns $-140,730,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis. Rhythm Pharmaceuticals employs 70 workers across the globe.

What is Rhythm Pharmaceuticals' official website?

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings